Shanghai Junshi Biosciences CoのEBIT margin
Shanghai Junshi Biosciences CoのEBIT marginは何ですか。
Shanghai Junshi Biosciences Co., Ltd.のEBIT marginは-81.46%です。
EBIT marginの定義は何ですか。
EBIT margin is a profitability ratio that measures earnings of the company as a percentage of revenue without taking into account the effect of taxes and interest.
ttm (trailing twelve months)
EBIT margin measures the profitability and operational efficiency of a company. It compares the amount of money that remains after the cost of goods and all operating expenses are subtracted from net revenue to sales. EBIT margin is calculated as earnings before interest and taxes divided by net revenue.
EBIT and EBIT margin evaluate how well a business manages its operations. Interest and taxes are not operating expenses and don’t impact operating efficiency. EBIT margin is usually used to compare operational efficiency and profitability of companies within the same industry. Taxes can vary by location thus excluding them from the calculation gives a better basis for comparing different companies.
EBIT and operating income are often used interchangeably, but there is a difference between them, which can cause the numbers to give different results. The key difference is that operating income does not include non-operating income, non-operating expenses, and other income.
OTCのセクタHealth CareにおけるEBIT marginの企業と比べるShanghai Junshi Biosciences Co
Shanghai Junshi Biosciences Coは何をしますか。
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Shanghai Junshi Biosciences Coと類似のebit margin
- Alnylam PharmaceuticalsのEBIT marginは-82.32%です。
- Jernigan CapitalのEBIT marginは-82.11%です。
- Asia-Pac InvestmentのEBIT marginは-81.91%です。
- Genetic TechnologiesのEBIT marginは-81.84%です。
- VBC Ferro AlloysのEBIT marginは-81.80%です。
- MICT IncのEBIT marginは-81.54%です。
- Shanghai Junshi Biosciences CoのEBIT marginは-81.46%です。
- The McClatchyのEBIT marginは-80.94%です。
- Blue Blends (India)のEBIT marginは-80.91%です。
- Genius Brands InternationalのEBIT marginは-80.90%です。
- Societe Francaise de Gestion et d'InvestissementのEBIT marginは-80.81%です。
- Syncom HealthcareのEBIT marginは-80.80%です。
- Carebook TechnologiesのEBIT marginは-80.69%です。